Home/Filings/4/0000950170-25-036591
4//SEC Filing

Halstead Michael 4

Accession 0000950170-25-036591

CIK 0001567514other

Filed

Mar 9, 8:00 PM ET

Accepted

Mar 10, 6:01 PM ET

Size

13.7 KB

Accession

0000950170-25-036591

Insider Transaction Report

Form 4
Period: 2025-03-06
Halstead Michael
SVP and General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-10+7,34525,064 total
  • Tax Payment

    Common Stock

    2025-03-10$131.24/sh3,757$493,06921,307 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-107,3450 total
    Common Stock (7,345 underlying)
  • Tax Payment

    Common Stock

    2025-03-06$131.19/sh6,718$881,33417,719 total
  • Exercise/Conversion

    Common Stock

    2025-03-06+13,13324,437 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-0613,13313,133 total
    Common Stock (13,133 underlying)
Footnotes (5)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of common stock.
  • [F4]On March 6, 2023, the reporting person was granted 39,398 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  • [F5]On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Documents

1 file

Issuer

Intra-Cellular Therapies, Inc.

CIK 0001567514

Entity typeother

Related Parties

1
  • filerCIK 0001521548

Filing Metadata

Form type
4
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 6:01 PM ET
Size
13.7 KB